Epidermal growth factor receptor 2 (ERBB2), a well-known oncogene of multiple cancers, such as breast cancer and ovarian cancer (Baxevanis et al., 2004), was found to be firmly connected with cancer occurrence, proliferation, metastasis, drug resistance, immune escape and poor prognosis (Dawood et al., 2009; Bates et al., 2018). This evidence concerns the gene ERBB2 and breast cancer.